PURPOSE: A retrospective study was conducted to investigate the prognostic significance of @entity9604 / @entity5316 fusion resulting from a cryptic t(12;21) in Japanese @entity1 with childhood B-precursor @entity981 ( @entity981 ). MATERIALS AND METHODS: Leukemic samples from 144 @entity1 with newly diagnosed @entity981 (104 with @entity2282 -positive B-precursor @entity981 , 11 with @entity2282 -negative B-precursor @entity981 , 5 with @entity981 , and 24 with @entity981 ) were analyzed by reverse-transcription polymerase chain reaction. RESULTS: The frequency of @entity1 with @entity9604 / @entity5316 was 16% (23 of 144) and all @entity1 with @entity9604 / @entity5316 also had @entity2282 -positive B-precursor @entity981 . @entity9604 / @entity5316 was not found in any samples from the @entity1 with @entity981 , @entity981 , or @entity2282 -negative B-precursor @entity981 . Among @entity1 with @entity2282 -positive B-precursor @entity981 , age, initial white blood cell count, and immunophenotype did not differ with @entity9604 / @entity5316 positivity, although the @entity1 were predominantly male (p < 0.01). Clinical outcomes of 94 @entity1 treated with recent protocols were analyzed. Five of the 21 (23.8%) @entity1 with @entity9604 / @entity5316 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among @entity1 with @entity9604 / @entity5316 fusion transcript than among those without it (87.3 +/- 8.7% versus 75.9 +/- 5.8%, respectively), the 5-year disease-free survival (DFS) rates of @entity1 with @entity9604 / @entity5316 fusion transcript and those without it were similar (64.0 +/- 13.5% versus 69.1 +/- 6.3%, respectively). However, for 57 @entity1 treated with the latest intensive protocol, the 4-year DFS rate was much higher for the @entity1 with @entity9604 / @entity5316 fusion transcript than for those without it (100.0% v.s. 69.6 +/- 8.4%, respectively, p = 0.1472). CONCLUSIONS: This study confirmed that @entity9604 / @entity5316 gene fusion is the most common genetic event in @entity981 in Japan and is restricted to @entity2282 -positive B-precursor @entity981 . Moreover, it was associated with an improved survival rate among @entity1 treated with intensive therapy. Therefore, these data suggest that the @entity1 with @entity9604 / @entity5316 may not necessarily be candidates for less aggressive treatment.

Prognostic significance of XXXX / @entity5316 fusion transcript in childhood B-precursor @entity981 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['B-ALL', 'T-ALL', 'pediatric ALL', 'ALL', 'acute lymphoblastic leukemia'] @entity9604 :: ('2120', 'Gene') :: ['TEL'] @entity2282 :: ('4311', 'Gene') :: ['CD10'] @entity5316 :: ('861', 'Gene') :: ['AML1']
@entity9604 :: (2120,Gene) :: ['TEL']
